Phathom Pharmaceuticals, Inc. (PHAT)

In the past six months, Phathom Pharmaceuticals' stock experienced notable events. As of February 6, 2026, the closing stock price was $12.58. The 52-week high was $18.31, set on December 23, 2025, while its 52-week low was $2.21. On January 8, 2026, the stock saw a significant daily drop of 13.72% around the time of a $130.0 million follow-on offering. Insider sentiment has been positive due to open-market purchases, and the stock has shown volatility, with a daily average of 7.91% over the last week.

Phathom Pharmaceuticals' products, particularly VOQUEZNA, experience demand seasonality. The first quarter of the year typically presents "seasonal headwinds" that temporarily soften retail pharmacy volume due to insurance plan resets, holiday disruptions, and deductible renewals. Despite these challenges, the company reported an 8% sequential growth in VOQUEZNA prescriptions in the first quarter of 2025.

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. Their primary product is vonoprazan, found in VOQUEZNA tablets, VOQUEZNA Triple Pak, and VOQUEZNA Dual Pak. These products are in Phase III clinical trials for treating erosive GERD, Helicobacter pylori infection, and are being investigated for non-erosive GERD and eosinophilic esophagitis.

Phathom Pharmaceuticals is headquartered in Florham Park, New Jersey, and primarily focuses its commercialization efforts for products like VOQUEZNA on the U.S. market.

Phathom Pharmaceuticals generally holds a "Moderate Buy" consensus rating from analysts, with an average rating score of 2.67. The company's brand reputation is supported by the commercial growth of VOQUEZNA, which saw a 28% increase in prescriptions filled over the second quarter of 2025. However, the company has faced challenges, including a substantial net loss in the third quarter of 2025, and an unfavorable FDA exclusivity decision.

Phathom Pharmaceuticals has significant institutional ownership, with 241 institutional owners holding 68,964,280 shares, representing 79.68% of the total shares outstanding. Major institutional owners include Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, Millennium Management Llc, Invesco Ltd., Carlyle Group Inc., BlackRock, Inc., Vanguard Group Inc, Ensign Peak Advisors, Inc., and NEA Management Company, LLC. Private equity firms also hold a substantial stake of 25%.